Abstract 1489P
Background
In light of the expanding utilization of electronic patient-reported outcomes (ePROs) in healthcare settings, their integration into the standard practice of palliative care remains uncertain. This investigation aimed to identify the determinants linked with adherence to ePRO utilization within a Cancer Network in Brazil.
Methods
Eligible patients had metastatic solid cancer with an expected survival of over 3 months. They were enrolled in monthly ePRO assessments using the Integrated Palliative Outcome Scale (IPOS). Patients failing to complete assessments received one reminder. We conducted multivariate regression analyses to examine the factors influencing adherence. Patient characteristics (age, gender, marital status, education level, and cancer type), along with initial responses on the IPOS, were included as predictors. Follow-up time within palliative care was controlled for in the analysis.
Results
A total of 494 patients were included, with a median age of 67 years (range: 22-94). Most were female (56.1%), married (58.9%), and had at least high school education (77.7%). Most were diagnosed with gastrointestinal (33.2%), breast (20.2%), and genitourinary (14.8%) cancers. Patients had a median follow-up time within palliative care of 10.5 months (range: 3-63 months). Notably, younger age (β=-0.3, SE=0.01, p=0.004), female gender (β=-0.7, SE=0.36, p=0.03) and higher education (β =0.1, SE = 0.06, p = 0.009) were associated with higher ePRO adherence. Interestingly, lower initial assessment score was linked with increased ePRO adherence (p=0.002). Patients experiencing loss of appetite (β=0.4, SE=0.18, p=0.01), having an anxious family member (β=0.3, SE=0.16, p=0.03), and expressing a desire for more information (β=0.2, SE=0.11, p=0.04) also demonstrated higher ePRO adherence.
Conclusions
Our findings underscore the need for tailored approaches to promote patient engagement and improve adherence to ePRO assessments in palliative care settings. Further research exploring interventions targeted at addressing these factors could enhance the integration of ePRO into routine clinical practice, ultimately leading to better patient outcomes and quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10